By 2030, will the FDA approve any drug in combination with a checkpoint blockade therapy that substantially reduces immune escape?
JeopolitikOne-OffSağlık ve Tıp3y
Manifold MarketsKYC yokDoğrulanmış sonuçlanma verisiOrta düzey kalibreGüncel topluluk tahmini
Evet 53.5%
Evet 53.5%Tahminciler
5
Soru türü
binary
Yöntem
Play-money forecasting platform
Kaynak türü
Tahmin
Piyasa verileri
1 saat önce güncellendi
Gecikmeli18 Kas 22 02:41 UTC1 Oca 30 08:00 UTC
Trendler
Kurallar
Checkpoint blockade therapy (also called immune checkpoint inhibitors) is an cancer therapy that works (roughly speaking) by preventing the cancer from disabling the immune system.
- There's a list of major immune checkpoint inhibitors here: https://en.wikipedia.org/wiki/Checkpoint_inhibitor
- A common issue with this kind of therapy is immune escape: the cancer mutates and escapes from the immune system in some other way, which makes the drug much less effective or even useless.
- You can read an overview of the topic here: https://sci-hub.se/10.1093/annonc/mdw217
- This market resolves YES if any combination therapy is approved that:
- Reduces immune escape by >= 10 percentage points over the course of two years according to any metric in an associated publication.
